Study of a drug combo for newly diagnosed AL amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been newly diagnosed with AL amyloidosis (a disease where abnormal proteins build up in your organs).
- You have a measurable level of abnormal proteins in your blood or urine.
- You are not a candidate for a stem cell transplant as your first treatment.
- Your heart, liver, and kidneys are working well enough, and you have no severe heart conditions.
- You have not had any previous treatment for AL amyloidosis or multiple myeloma, except for a small amount of steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This study tests belantamab mafodotin, a medicine designed to target amyloid-producing abnormal cells, in people with relapsed or refractory AL (light-chain) amyloidosis. It’s aimed at improving blood and organ-related signs of the disease after earlier treatments have stopped working.
This trial tests a new targeted medicine called elranatamab for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs. It aims to see if this treatment can help control the disease.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This trial tests a combination of two new drugs, sonrotoclax and a BCMA bispecific antibody, for people newly diagnosed with AL amyloidosis. The treatment aims to target and destroy the abnormal cells that cause the disease, potentially improving outcomes.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.